10,000 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Bought by Waycross Partners LLC

Waycross Partners LLC acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,000 shares of the medical equipment provider’s stock, valued at approximately $1,217,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Schechter Investment Advisors LLC raised its position in Zimmer Biomet by 21.6% in the third quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider’s stock valued at $476,000 after purchasing an additional 752 shares during the last quarter. Atria Wealth Solutions Inc. raised its position in shares of Zimmer Biomet by 5.9% during the third quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider’s stock worth $2,312,000 after acquiring an additional 1,144 shares during the last quarter. International Assets Investment Management LLC raised its position in shares of Zimmer Biomet by 11,244.9% during the fourth quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock worth $8,146,000 after acquiring an additional 66,345 shares during the last quarter. Amalgamated Bank raised its position in shares of Zimmer Biomet by 3.0% during the third quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock worth $6,303,000 after acquiring an additional 1,631 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its position in shares of Zimmer Biomet by 37.5% during the fourth quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock worth $18,981,000 after acquiring an additional 42,539 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ZBH shares. Raymond James raised their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. StockNews.com downgraded Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. JPMorgan Chase & Co. raised their target price on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Citigroup raised their target price on Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded down $1.43 during mid-day trading on Tuesday, reaching $120.28. 1,428,306 shares of the company’s stock were exchanged, compared to its average volume of 1,445,902. The business’s fifty day simple moving average is $125.83 and its 200 day simple moving average is $119.92. The firm has a market capitalization of $24.71 billion, a PE ratio of 24.60, a P/E/G ratio of 2.19 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $149.25. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. Zimmer Biomet’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company posted $1.88 earnings per share. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 19.63%.

Insider Buying and Selling

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.70% of the stock is currently owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.